Incyte

INCY Health Care Market cap $24.8B as of Sep 14, 2026 16:00 ET S&P 500

Q1 FY26 Jan 1 – Mar 31, 2026 reported Apr 28, 2026

Revenue$1.27B +21% year over year

Gross profit$1.17B 92% margin

Operating profit$0.30B 24% margin

Net profit$0.30B 24% margin

The numbers behind the diagram

All figures in billions of U.S. dollars, for Q1 FY26 (period ends Mar 31, 2026).
Item	Value	Share of revenue	Year over year
Revenue	1.27	100%	+21%
Cost of revenue	−0.11	8%
Gross profit	1.17	92% margin	−1pp
R&D	−0.52	40%	−1pp
SG&A	−0.33	26%	−5pp
Other	−0.02	2%	+0pp
Operating profit	0.30	24% margin	+4pp
Other income, net	0.04
Tax	−0.04
Net profit	0.30	24% margin	+9pp

The filing's own split of this revenue lists a part named after the whole, so only the total is shown.

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q4 FY25 (period ends Dec 31, 2025).
Item	Value	Share of revenue	Year over year
Revenue	1.51	100%	+28%
Cost of revenue	−0.12	8%
Gross profit	1.39	92% margin	−1pp
R&D	−0.61	41%	+1pp
SG&A	−0.39	26%	−2pp
Other	−0.05	3%
Operating profit	0.34	22% margin	−3pp
Other income, net	0.05
Tax	−0.09
Net profit	0.30	20% margin	+3pp

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q3 FY25 (period ends Sep 30, 2025).
Item	Value	Share of revenue	Year over year
Revenue	1.37	100%	+20%
Jakafi	0.79	58%	+7%
Opzelura	0.19	14%	+35%
Product royalty	0.17	13%	+9%
Niktimvo	0.05	3%
Other	0.05	3%
Milestone & contract	0.05	3%	+150%
Minjuvi/monjuvi	0.04	3%	+34%
Iclusig	0.04	3%	+26%
Cost of revenue	−0.10	7%
Gross profit	1.27	93% margin	+0pp
R&D	−0.49	36%	−13pp
SG&A	−0.33	24%	−3pp
Operating profit	0.44	32% margin	+20pp
Other income, net	0.04
Tax	−0.06
Net profit	0.42	31% margin	+22pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q2 FY25 (period ends Jun 30, 2025).
Item	Value	Share of revenue	Year over year
Revenue	1.22	100%	+16%
Jakafi	0.76	63%
Opzelura	0.16	13%
Product royalty	0.15	12%
Niktimvo	0.04	3%
Iclusig	0.03	3%
Minjuvi/monjuvi	0.03	3%
Pemazyre	0.02	2%
Other	0.01	1%
Cost of revenue	−0.08	6%
Gross profit	1.14	94% margin	+1pp
R&D	−0.28	23%	−68pp
SG&A	−0.33	27%	−2pp
Operating profit	0.53	44% margin	+89pp
Other income, net	0.03
Tax	−0.15
Net profit	0.41	33% margin	+76pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q4 FY24 (period ends Dec 31, 2024).
Item	Value	Share of revenue	Year over year
Revenue	1.18	100%	+16%
Product	1.02	86%	+18%
Royalty	0.16	14%	+6%
ZYNYZ	<0.01	0%	+136%
Cost of revenue	−0.09	7%
Gross profit	1.09	92% margin	−1pp
R&D	−0.46	39%	−4pp
SG&A	−0.33	28%	−1pp
Operating profit	0.30	26% margin	+7pp
Other income, net	0.01
Tax	−0.11
Net profit	0.20	17% margin	−3pp

Filing on EDGAR This quarter on its own page

Financial health

The balance sheet, the quarter's capital flow, the debt schedule and the capital structure of the quarter shown above.

Every set of results we hold, newest first. Open one on its own page.

Quarter	Period	Reported	Revenue	Year over year	Operating margin	Net profit	Net margin
Q1 FY26 Jan 1 – Mar 31, 2026 reported Apr 28, 2026 Operating margin 24% Net profit $0.30B	Jan 1 – Mar 31, 2026	Apr 28, 2026	$1.27B	+21%	24%	$0.30B	24%
Q4 FY25 Oct 1 – Dec 31, 2025 reported Feb 10, 2026 Operating margin 22% Net profit $0.30B	Oct 1 – Dec 31, 2025	Feb 10, 2026	$1.51B	+28%	22%	$0.30B	20%
Q3 FY25 Jul 1 – Sep 30, 2025 reported Oct 28, 2025 Operating margin 32% Net profit $0.42B	Jul 1 – Sep 30, 2025	Oct 28, 2025	$1.37B	+20%	32%	$0.42B	31%
Q2 FY25 Apr 1 – Jun 30, 2025 reported Jul 29, 2025 Operating margin 44% Net profit $0.41B	Apr 1 – Jun 30, 2025	Jul 29, 2025	$1.22B	+16%	44%	$0.41B	33%
Q4 FY24 Oct 1 – Dec 31, 2024 reported Feb 10, 2025 Operating margin 26% Net profit $0.20B	Oct 1 – Dec 31, 2024	Feb 10, 2025	$1.18B	+16%	26%	$0.20B	17%